-
1
-
-
84871055765
-
-
American Cancer Society, Published, Accessed Dec 21, 2011
-
American Cancer Society. What is non-small cell lung cancer. http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer. Published 2011. Accessed Dec 21, 2011.
-
(2011)
What is Non-small Cell Lung Cancer
-
-
-
2
-
-
0036676214
-
Estimating health care costs related to cancer treatment from SEER-Medicare data
-
Brown ML, Riley G F, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40(8) (suppl):IV 104-117.
-
(2002)
Med Care
, vol.40
, Issue.8 SUPPL. 4
, pp. 104-117
-
-
Brown, M.L.1
Riley, G.F.2
Schussler, N.3
Etzioni, R.4
-
3
-
-
0003243818
-
The epidemiology of small cell lung carcinoma [abstract 1216]
-
Page N, Read W, Tierney R, et al. The epidemiology of small cell lung carcinoma [abstract 1216]. Proc Am Soc Clin Oncol. 2002;21:305.
-
(2002)
Proc Am Soc Clin Oncol
, vol.305
, pp. 21
-
-
Page, N.1
Read, W.2
Tierney, R.3
-
4
-
-
33745645399
-
Salvage therapy for advanced non-small cell lung cancer: Factors infl uencing treatment selection
-
Ramalingam S, Sandler AB. Salvage therapy for advanced non-small cell lung cancer: factors infl uencing treatment selection. Oncologist. 2006;11(6):655-665.
-
(2006)
Oncologist
, vol.11
, Issue.6
, pp. 655-665
-
-
Ramalingam, S.1
Sandler, A.B.2
-
5
-
-
10044284428
-
Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status
-
Govindan R, Garfi eld DH. Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. Semin Oncol. 2004;31(6) (suppl 11):27-31.
-
(2004)
Semin Oncol
, vol.31
, Issue.6 SUPPL. 11
, pp. 27-31
-
-
Govindan, R.1
Garfield, D.H.2
-
6
-
-
34548620214
-
Pharmacy benefi t spending on oral chemotherapy drugs
-
Curtiss FR. Pharmacy benefi t spending on oral chemotherapy drugs. J Manag Care Pharm. 2006;12(7):570-577.
-
(2006)
J Manag Care Pharm
, vol.12
, Issue.7
, pp. 570-577
-
-
Curtiss, F.R.1
-
7
-
-
22044445517
-
National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-132.
-
(2005)
N Engl J Med
, vol.353
, Issue.2
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues, P.J.2
Ciuleanu, T.3
-
8
-
-
79955037760
-
Increase in oral cancer drugs raises thorny issues for oncology practices
-
Hede K. Increase in oral cancer drugs raises thorny issues for oncology practices. J Natl Cancer Inst. 2009;101(22):1534-1536.
-
(2009)
J Natl Cancer Inst
, vol.101
, Issue.22
, pp. 1534-1536
-
-
Hede, K.1
-
9
-
-
4344640030
-
Under-dosing study raises questions about ways to improve regimen adherence
-
Webb T. Under-dosing study raises questions about ways to improve regimen adherence. J Natl Cancer Inst. 2004;96(16):1201-1202.
-
(2004)
J Natl Cancer Inst
, vol.96
, Issue.16
, pp. 1201-1202
-
-
Webb, T.1
-
10
-
-
44249094168
-
Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (Pts) on imatinib (IM): 2006 ASCP Annual Meeting Proceedings, part I
-
Tsang J, Rudychev I, Pescatore S. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (Pts) on imatinib (IM): 2006 ASCP Annual Meeting Proceedings, part I. J Clin Oncol. 2006;24(18S)(suppl):6119.
-
(2006)
J Clin Oncol
, vol.24
, Issue.18 SUPPL.
, pp. 6119
-
-
Tsang, J.1
Rudychev, I.2
Pescatore, S.3
-
11
-
-
78349255323
-
Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasat-inib in chronic myeloid leukemia
-
Wu EQ, Guerin A, Yu A P, Bollu VK, Guo A, Griffi n JD. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasat-inib in chronic myeloid leukemia. Curr Med Res Opin. 2010;26(12):2861-2869.
-
(2010)
Curr Med Res Opin
, vol.26
, Issue.12
, pp. 2861-2869
-
-
Wu, E.Q.1
Guerin, A.2
Yu, A.P.3
Bollu, V.K.4
Guo, A.5
Griffin, J.D.6
-
12
-
-
34249782019
-
Treatment interruptions and non-adherence with imatinib and associated healthcare costs: A retrospective analysis among managed care patients with chronic myelogenous leukaemia
-
Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmaco-economics. 2007;25(6):481-496.
-
(2007)
Pharmaco-economics
, vol.25
, Issue.6
, pp. 481-496
-
-
Darkow, T.1
Henk, H.J.2
Thomas, S.K.3
-
13
-
-
77954249679
-
Factors infl uencing cost-related nonadherence to medication in older adults: A conceptually based approach
-
Zivin K, Ratliff S, Heisler MM, Langa KM, Piette JD. Factors infl uencing cost-related nonadherence to medication in older adults: a conceptually based approach. Value Health. 2010;13(4):338-345.
-
(2010)
Value Health
, vol.13
, Issue.4
, pp. 338-345
-
-
Zivin, K.1
Ratliff, S.2
Heisler, M.M.3
Langa, K.M.4
Piette, J.D.5
-
14
-
-
30644474050
-
A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures
-
Piette JD, Heisler M, Horne R, Caleb Alexander G. A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures. Soc Sci Med. 2006;62(4):846-857.
-
(2006)
Soc Sci Med
, vol.62
, Issue.4
, pp. 846-857
-
-
Piette, J.D.1
Heisler, M.2
Horne, R.3
Caleb Alexander, G.4
-
15
-
-
78651093475
-
Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer
-
Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat. 2011;125(1):191-200.
-
(2011)
Breast Cancer Res Treat
, vol.125
, Issue.1
, pp. 191-200
-
-
Sedjo, R.L.1
Devine, S.2
-
16
-
-
79952115242
-
Nonadherence in patients with breast cancer receiving oral therapies
-
Moore S. Nonadherence in patients with breast cancer receiving oral therapies. Clin J Oncol Nurs. 2010;14(1):41-47.
-
(2010)
Clin J Oncol Nurs
, vol.14
, Issue.1
, pp. 41-47
-
-
Moore, S.1
-
17
-
-
84869846879
-
Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia
-
St. Charles M, Bollu VK, Hornyak E, Coombs J, Blanchette CM, DeAngelo D. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. ASH Annual Meeting Abstracts. 2009 114:2209.
-
(2209)
ASH Annual Meeting Abstracts
, vol.2009
, pp. 114
-
-
Charles, M.1
Bollu, V.K.2
Hornyak, E.3
Coombs, J.4
Blanchette, C.M.5
Deangelo, D.6
-
18
-
-
77649221871
-
Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients
-
Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin. 2010;26(1):61-69.
-
(2010)
Curr Med Res Opin
, vol.26
, Issue.1
, pp. 61-69
-
-
Wu, E.Q.1
Johnson, S.2
Beaulieu, N.3
-
19
-
-
56249122892
-
Behavioral and psychological predictors of chemotherapy adherence in patients with advanced non-small cell lung cancer
-
Greer JA, Pirl W F, Park ER, Lynch TJ, Temel JS. Behavioral and psychological predictors of chemotherapy adherence in patients with advanced non-small cell lung cancer. J Psychosom Res. 2008;65(6):549-552.
-
(2008)
J Psychosom Res
, vol.65
, Issue.6
, pp. 549-552
-
-
Greer, J.A.1
Pirl, W.F.2
Park, E.R.3
Lynch, T.J.4
Temel, J.S.5
-
20
-
-
43949090868
-
Second-line and third-line chemotherapy for lung cancer: Use and cost
-
Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM. Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care. 2008;14(5):297-306.
-
(2008)
Am J Manag Care
, vol.14
, Issue.5
, pp. 297-306
-
-
Ramsey, S.D.1
Martins, R.G.2
Blough, D.K.3
Tock, L.S.4
Lubeck, D.5
Reyes, C.M.6
-
21
-
-
22544468809
-
Estimating medication persistency using administrative claims data
-
Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11(7):449-457.
-
(2005)
Am J Manag Care
, vol.11
, Issue.7
, pp. 449-457
-
-
Sikka, R.1
Xia, F.2
Aubert, R.E.3
-
22
-
-
33748343357
-
Methods for evaluation of medication adherence and persistence using automated databases
-
Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565-574.
-
(2006)
Pharmacoepidemiol Drug Saf
, vol.15
, Issue.8
, pp. 565-574
-
-
Andrade, S.E.1
Kahler, K.H.2
Frech, F.3
Chan, K.A.4
-
23
-
-
80052695744
-
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions
-
Streeter SB, Schwartzberg L, Husain N, Johnsrud M. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract. 2011;7(3)(suppl):46s-51s.
-
(2011)
J Oncol Pract
, vol.7
, Issue.3 SUPPL.
-
-
Streeter, S.B.1
Schwartzberg, L.2
Husain, N.3
Johnsrud, M.4
-
24
-
-
79959761280
-
The use of erlotinib in daily practice: A study on adherence and patients' experiences
-
Timmers L, Boons CC, Mangnus D, et al. The use of erlotinib in daily practice: a study on adherence and patients' experiences. BMC Cancer. 2011;11:284.
-
(2011)
BMC Cancer
, vol.11
, pp. 284
-
-
Timmers, L.1
Boons, C.C.2
Mangnus, D.3
-
25
-
-
79955698843
-
Perspectives on adherence and persistence with oral medications for cancer treatment
-
Hohneker J, Shah-Mehta S, Brandt PS. Perspectives on adherence and persistence with oral medications for cancer treatment. J Oncol Pract. 2011;7(1): 65-67.
-
(2011)
J Oncol Pract
, vol.7
, Issue.1
, pp. 65-67
-
-
Hohneker, J.1
Shah-Mehta, S.2
Brandt, P.S.3
-
26
-
-
79960954634
-
Patient adherence to oral anticancer drugs: An emerging issue in modern oncology
-
Foulon V, Schöffski P, Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg. 2011;66(2):85-96.
-
(2011)
Acta Clin Belg
, vol.66
, Issue.2
, pp. 85-96
-
-
Foulon, V.1
Schöffski, P.2
Wolter, P.3
-
27
-
-
39149111976
-
Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer
-
Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):523-526.
-
(2008)
J Clin Oncol
, vol.26
, Issue.4
, pp. 523-526
-
-
Partridge, A.H.1
Lafountain, A.2
Mayer, E.3
Taylor, B.S.4
Winer, E.5
Asnis-Alibozek, A.6
-
28
-
-
0037441639
-
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
-
Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21(4): 602-606.
-
(2003)
J Clin Oncol
, vol.21
, Issue.4
, pp. 602-606
-
-
Partridge, A.H.1
Wang, P.S.2
Winer, E.P.3
Avorn, J.4
-
29
-
-
33847373003
-
Early discontinuation of tamoxifen: A lesson for oncologists
-
Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer. 2007;109(5):832-839.
-
(2007)
Cancer
, vol.109
, Issue.5
, pp. 832-839
-
-
Barron, T.I.1
Connolly, R.2
Bennett, K.3
Feely, J.4
Kennedy, M.J.5
-
30
-
-
0035863386
-
Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women
-
Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol. 2001;19(2):322-328.
-
(2001)
J Clin Oncol
, vol.19
, Issue.2
, pp. 322-328
-
-
Demissie, S.1
Silliman, R.A.2
Lash, T.L.3
-
31
-
-
84869765947
-
Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer
-
Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2004;109(5):832-839.
-
(2004)
J Clin Oncol
, vol.109
, Issue.5
, pp. 832-839
-
-
Fink, A.K.1
Gurwitz, J.2
Rakowski, W.3
Guadagnoli, E.4
Silliman, R.A.5
-
32
-
-
70350728600
-
Cost-related medication nonadherence after implementation of Medicare Part D, 2006-2007
-
Madden JM, Graves AJ, Ross-Degnan D, Briesacher BA, Soumerai SB. Cost-related medication nonadherence after implementation of Medicare Part D, 2006-2007. JAMA. 2009;302(16):1755-1756.
-
(2009)
JAMA
, vol.302
, Issue.16
, pp. 1755-1756
-
-
Madden, J.M.1
Graves, A.J.2
Ross-Degnan, D.3
Briesacher, B.A.4
Soumerai, S.B.5
-
33
-
-
79955678058
-
Medication safety of fi ve oral chemotherapies: A proactive risk assessment
-
Weingart SN, Spencer J, Bula D, et al. Medication safety of fi ve oral chemotherapies: a proactive risk assessment. J Oncol Pract. 2011;7(1):2-6.
-
(2011)
J Oncol Pract
, vol.7
, Issue.1
, pp. 2-6
-
-
Weingart, S.N.1
Spencer, J.2
Bula, D.3
-
34
-
-
78651071074
-
Approval summary: Erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)
-
E3
-
Cohen MH, Johnson JR, Chattopadhyat S, et al. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist. 2010;15(3):1344-1351. E3
-
(2010)
Oncologist
, vol.15
, Issue.3
, pp. 1344-1351
-
-
Cohen, M.H.1
Johnson, J.R.2
Chattopadhyat, S.3
|